TI
SYRE icon

Trexquant Investment’s Spyre Therapeutics SYRE Stock Holding History

Trexquant Investment’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-805
Closed -$158K – 1453
2020
Q4 		$158K Buy
+805
New +$167K 0.02% 928
2020
Q3 		– Sell
-547
Closed -$126K – 1522
2020
Q2 		$126K Buy
+547
New +$104K 0.01% 1105
2019
Q1 		– Sell
-618
Closed -$116K – 1304
2018
Q4 		$116K Buy
+618
New +$131K 0.01% 982

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Trexquant Investment's SYRE Position: Q1 2021 in Review

Trexquant Investment sold out of Spyre Therapeutics (SYRE) in Q1 2021, closing a stake of 805 shares — an estimated $158K sold.

Trexquant Investment first reported a position in SYRE in Q4 2018 and held it in 3 quarters. The position peaked at $158K in Q4 2020. 84 funds tracked by Wall St. Rank hold SYRE as of Q1 2021.

  • Trexquant Investment reported no remaining Spyre Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Trexquant Investment sold 805 Spyre Therapeutics shares in Q1 2021, an estimated $158K.
  • Trexquant Investment first reported a position in Spyre Therapeutics in Q4 2018 and held it in 3 quarters.
  • Trexquant Investment's Spyre Therapeutics position peaked at $158K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2021.

Based on Trexquant Investment's 13F filing for Q1 2021, filed 13 May 2021.